glp-1 obesity drug news today september 2025 15 GLP-1 Drugs: 2025 Pulse Survey (U.S.) GLP-1 Weight-Loss Drug Demonstration Begins

Am J Ophthalmol 2025;274:24-31.ArticlePubMed 100

Figure 26: Photograph of Professor Jens Holst with Dr Karen Thorne, a member of his laboratory, carrying out an experiment with a perfused pig pancreas in the 1990s, credit: Holst

Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue Semaglutide

GLP-1RAs, particularly Liraglutide exert protective effects by suppressing inflammasome activation and downstream pyroptotic responses.In H9c2 cells

Schmidt T

Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]